These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Xia H; Ooi LL; Hui KM Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579 [TBL] [Abstract][Full Text] [Related]
3. Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma. Kawai T; Yasuchika K; Ishii T; Katayama H; Yoshitoshi EY; Ogiso S; Kita S; Yasuda K; Fukumitsu K; Mizumoto M; Hatano E; Uemoto S Clin Cancer Res; 2015 Jul; 21(13):3081-91. PubMed ID: 25820415 [TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Senturk S; Mumcuoglu M; Gursoy-Yuzugullu O; Cingoz B; Akcali KC; Ozturk M Hepatology; 2010 Sep; 52(3):966-74. PubMed ID: 20583212 [TBL] [Abstract][Full Text] [Related]
5. Activation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma. Dhanasekaran R; Nakamura I; Hu C; Chen G; Oseini AM; Seven ES; Miamen AG; Moser CD; Zhou W; van Kuppevelt TH; van Deursen JM; Mounajjed T; Fernandez-Zapico ME; Roberts LR Hepatology; 2015 Apr; 61(4):1269-83. PubMed ID: 25503294 [TBL] [Abstract][Full Text] [Related]
6. Compound Astragalus and Salvia miltiorrhiza extracts suppress hepatocarcinogenesis by modulating transforming growth factor-β/Smad signaling. Hu X; Rui W; Wu C; He S; Jiang J; Zhang X; Yang Y J Gastroenterol Hepatol; 2014 Jun; 29(6):1284-91. PubMed ID: 24329763 [TBL] [Abstract][Full Text] [Related]
7. A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Rojas A; Zhang P; Wang Y; Foo WC; Muñoz NM; Xiao L; Wang J; Gores GJ; Hung MC; Blechacz B Neoplasia; 2016 Jun; 18(6):371-86. PubMed ID: 27292026 [TBL] [Abstract][Full Text] [Related]
8. Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine. Zhang PP; Wang PQ; Qiao CP; Zhang Q; Zhang JP; Chen F; Zhang X; Xie WF; Yuan ZL; Li ZS; Chen YX Cancer Lett; 2016 Jun; 376(1):95-103. PubMed ID: 26945965 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347 [TBL] [Abstract][Full Text] [Related]
10. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma? Ceballos MP; Parody JP; Alvarez Mde L; Ingaramo PI; Carnovale CE; Carrillo MC Biochem Pharmacol; 2011 Dec; 82(11):1682-91. PubMed ID: 21843516 [TBL] [Abstract][Full Text] [Related]
11. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. Yu D; Shin HS; Lee YS; Lee YC Lab Invest; 2014 Dec; 94(12):1370-81. PubMed ID: 25286029 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Fang Y; Xue JL; Shen Q; Chen J; Tian L Hepatology; 2012 Jun; 55(6):1852-62. PubMed ID: 22234835 [TBL] [Abstract][Full Text] [Related]
13. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma. Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552 [TBL] [Abstract][Full Text] [Related]
14. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879 [TBL] [Abstract][Full Text] [Related]
15. Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction. Yang YM; Lee CG; Koo JH; Kim TH; Lee JM; An J; Kim KM; Kim SG Oncotarget; 2015 Aug; 6(22):19055-69. PubMed ID: 25965999 [TBL] [Abstract][Full Text] [Related]
16. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growth. Matsuzaki K; Date M; Furukawa F; Tahashi Y; Matsushita M; Sugano Y; Yamashiki N; Nakagawa T; Seki T; Nishizawa M; Fujisawa J; Inoue K Hepatology; 2000 Aug; 32(2):218-27. PubMed ID: 10915727 [TBL] [Abstract][Full Text] [Related]
17. Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling. Xu Q; Xu HX; Li JP; Wang S; Fu Z; Jia J; Wang L; Zhu ZF; Lu R; Yao Z Oncotarget; 2017 Mar; 8(10):16972-16987. PubMed ID: 28199981 [TBL] [Abstract][Full Text] [Related]
18. Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Kishikawa T; Otsuka M; Tan PS; Ohno M; Sun X; Yoshikawa T; Shibata C; Takata A; Kojima K; Takehana K; Ohishi M; Ota S; Noyama T; Kondo Y; Sato M; Soga T; Hoshida Y; Koike K Oncotarget; 2015 Apr; 6(10):8339-52. PubMed ID: 25826076 [TBL] [Abstract][Full Text] [Related]
19. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells. Li Q; Liu G; Shao D; Wang J; Yuan H; Chen T; Zhai R; Ni W; Tai G Int J Biochem Cell Biol; 2015 Feb; 59():116-25. PubMed ID: 25526895 [TBL] [Abstract][Full Text] [Related]
20. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]